THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) today announced that the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) has communicated to Marketing Authorization Holders (MAHs) of epoetins a proposal for amending prescribing information for Erythropoiesis Stimulating Agents (ESAs) in the European Union, including Aranesp® (darbepoetin alfa).
